Cyclin G-Associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3342-3350

  Susa, Michiro ^a   Choy, Edwin ^a   Liu, Xianzhe ^a   Schwab, Joseph ^a   Hornicek, Francis J ^a   Mankin, Henry ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN G ASSOCIATED KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN SERINE THREONINE KINASE; SOMATOMEDIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LENTIVIRUS; OSTEOSARCOMA; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CELL SURFACE; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS;

EID: 78650473271     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0637     Document Type: Article

References (42)

1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2010;152:3-13.
2. Demetri GD, von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
3. Kanaoka Y, Kimura SH, Okazaki I, Ikeda M, Nojima H. GAK: A cyclin G associated kinase contains a tensin/auxilin-like domain. FEBS Lett 1997;402:73-80.
4. Kimura SH, Tsuruga H, Yabuta N, Endo Y, Nojima H. Structure, expression, and chromosomal localization of human GAK. Genomics 1997;44:179-87. (Pubitemid 27415542)
5. Ahle S, Ungewickell E. Auxilin, a newly identified clathrin-associated protein in coated vesicles from bovine brain. J Cell Biol 1990;111: 19-29.
6. Greener T, Zhao X, Nojima H, Eisenberg E, Greene LE. Role of cyclin G-associated kinase in uncoating clathrin-coated vesicles from nonneuronal cells. J Biol Chem 2000;275:1365-70.
7. Umeda A, Meyerholz A, Ungewickell E. Identification of the universal cofactor (auxilin 2) in clathrin coat dissociation. Eur J Cell Biol 2000;79:336-42.
8. Gall WE, Higginbotham MA, Chen C, Ingram MF, Cyr DM, Graham TR. The auxilin-like phosphoprotein Swa2p is required for clathrin function in yeast. Curr Biol 2000;10:1349-58.
9. Pishvaee B, Costaguta G, Yeung BG, Ryazanstsein S, Greener T, Greene LE, et al. A yeast DNA J protein required for uncoating of clathrin-coated vesicles in vivo. Nat Cell Biol 2000;2:958-63.
10. Greener T, Grant B, Zhang Y, Wu X, Greene LE, Hirsh D, et al. Caenorhabditis elegans auxilin: A J-domain protein essential for clathrin-mediated endocytosis in vivo. Nat Cell Biol 2001;3:215-9.
11. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994;54:2803-7.
12. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004;92:77-91.
13. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, et al. Insulinlike growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 2009;8: 2122-30.
14. Pollak MN, Polychronakos C, Richard M. Insulinlike growth factor I: A potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990;82:301-5.
15. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998;69:21-7.
16. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64:2047-53.
17. Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA, et al. Epidermal growth factor receptor in osteosarcoma: Expression and mutational analysis. Hum Pathol 2007;38:1184-91.
18. Oda Y, Wehrmann B, Radig K, Walter H, Rose I, Neumann W, et al. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: Its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 1995;141:97-103.
19. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008;113:1453-61.
20. Duan Z, Ji D, Weinstein EJ, Susa M, Choy E, Yang C, et al. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett 2010;293:220-9.
21. Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5(5):e10764.
22. Yang C, Ji D, Weinstein EJ, Hornicek FJ, Wood KB, Liu X, et al. The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 2010;31:552-8.
23. Yague E, Arance A, Kubitza L, O'Hare M, Jat P, Ogilvie CM, et al. Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res 2007;67:1130-7.
24. Susa M, Iyer AK, Ryu K, Hornicek FJ, Mankin H, Amiji MM, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMCCancer 2009;9:399.
25. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559-70.
26. Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 2006;12:5182-9.
27. Jimeno A, Li J, Messersmith WA, Laheru D, Rudk MA, Maniar M, et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-10.
28. Mross K, Frost A, Steinbild S, Hedborn S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:5511-7.
29. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
30. Kaye SB. Reversal of drug resistance in ovarian cancer: Where do we go from here?J Clin Oncol 2008;26:2616-8.
31. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-83.
32. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115: 895-902.
33. Korolchuk VI, Banting G. CK2 and GAK/auxilin2 are major protein kinases in clathrin-coated vesicles. Traffic 2002;3:428-39.
34. Newmyer SL, Christensen A, Sever S. Auxilin-dynamin interactions link the uncoating ATPase chaperone machinery with vesicle formation. Dev Cell 2003;4:929-40.
35. Jiang R, Gao B, Prasad K, Greene LE, Eisenberg E. Hsc70 chaperones clathrin and primes it to interact with vesicle membranes. J Biol Chem 2000;275:8439-47.
36. Yim YI, Scarselletta S, Zang F, Wu X, Lee DW, Kang YS, et al. Exchange of clathrin, AP2 and epsin on clathrin-coated pits in permeabilized tissue culture cells. J Cell Sci 2005;118:2405-13.
37. Zhang CX, Engqvist-Goldstein AE, Carreno S, Owen DJ, Smythe E, Drubin DG. Multiple roles for cyclin G-associated kinase in clathrinmediated sorting events. Traffic 2005;6:1103-13.
38. Zhang L, Gjoerup O, Roberts TM. The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling. Proc Natl Acad Sci U S A 2004;101:10296-301.
39. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010;115:1594-604.
40. Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, et al. Cyclin G-associated kinase: A novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer 2006;118:1108-19.
41. Vieira AV, Lamaze C, Schmid SL. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 1996;274:2086-9.
42. Bai T, Seebald JL, Kim KE, Ding HM, Szeto DP, Chang HC. Disruption of zebrafish cyclin G-associated kinase (GAK) function impairs the expression of Notch-dependent genes during neurogenesis and causes defects in neuronal development. BMC Dev Biol 2010;10:7.